2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Great Hall AD
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Research, Fundamental Science, AML, Translational Research
PAPER

553 LAIR1-targeting CAR T-cells eliminate AML in mouse and human preclinical models

Valencia Williams, Yiyun Peng2, Sophia Hani3, Kyle Smith4, Rita Ahmad, MD5, Naveen Premnath, MD6, Dallas Flies, PhD7, Tae Kon Kim, MD, PhD8, Bruce Blazar, MD, PhD9, Cameron McDonald-Hyman, MD, PhD10
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, United States
3 University of Minnesota, Minneapolis, United States
4 University of Minnesota, Minneapolis, United States
5 University of North Dakota, Grand Forks, North Dakota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 NextCure Inc., Beltsville, Maryland, United States
8 Vanderbilt University Medical Center, Nashville, Tennessee, United States
9 University of Minnesota, Minneapolis, United States
10 University of Minnesota, Minneapolis, Minnesota, United States

Acute myeloid leukemia (AML) is a highly aggressive malignancy, with a 50-60% mortality rate in the first 2 years after diagnosis and few effective treatment options if chemotherapy fails to induce a remission. There is a clinical need to develop new AML-directed therapies. Chimeric antigen receptor (CAR) T-cells can induce complete remissions in patients with CD19+ malignancies. However, CAR T-cell therapies for AML have not been successful, in part due to the inability to identify targets on AML that are not shared with non-malignant cells.

 

LAIR1 (leukocyte-associated immunoglobulin-like receptor-1) is an immunosuppressive collagen binding protein recently identified to be highly expressed on AML blasts, but only low levels on non-hematopoietic cells and non-pathogenic hematopoietic cells. In murine preclinical studies, LAIR1 was shown to be critical for AML pathogenesis. Therefore, we hypothesized that LAIR1 may be an ideal target for AML-specific therapies. To test this hypothesis, we developed human and mouse LAIR1-targeting CAR T-cells.

 

We confirmed and extended the previous study showing high LAIR1 expression on AML blasts. Flow cytometry profiling of deidentified diagnostic bone marrow aspirate samples from 23 AML patients across ELN 2022 risk stratifications (16 adverse, 5 favorable, 2 intermediate) showed that all AML blasts stained strongly for LAIR1 (compared to isotype), with higher LAIR1 expression on AML blasts (mean MFI 2801) compared to mature non-malignant myeloid cells (CD45+CD34-CD11b+CD64+; mean MFI 1319), irrespective of ELN risk group (p=0.02). AML blasts also demonstrated significantly higher LAIR1 expression compared to CD33 (mean MFI 959; p=0.0005) and CD123 (mean MFI 363; p<0.0001), each of which have been utilized as CAR targets for AML.

 

Human LAIR1 CAR T-cells first were evaluated in AML elimination studies in vitro. Control transduced or LAIR1 CAR T-cells were co-cultured with MOLM13 or U937 AML cell lines, each of which express high levels of LAIR1. Tumor:T-cell ratios included 2:1, 1:1 and 0:1. After 48H, CAR T-cells demonstrated >99% elimination of each AML cell line at both 2:1 and 1:1 ratios, with significantly higher overall AML elimination vs. control T-cells (p<0.0001 for MOLM13, p<0.001 for U937). Murine experiments with control and LAIR1 CAR T-cells were conducted in a similar fashion, but with two distinct LAIR1+ murine AML cell lines, MLL-AF9 and C1498. Murine CAR T-cells also demonstrated significantly higher AML elimination vs. controls (p<0.001 for both MLL-AF9 and C1498). Human results were replicated with 2 distinct T-cell doors and murine results were replicated in 3 separate experiments.

 

Next, we evaluated in vivo LAIR1 CAR T-cell efficacy. Cyclophosphamide (300mg/kg) pre-conditioned (D-1) C57Bl/b (B6) recipients were given 0.5x106 C1498 AML cells ± 2.5x106 control or CAR T-cells (D0). In pooled data from 3 experiments, mice given CAR T-cells demonstrated significantly higher overall survival compared to controls (45% survival D50 vs 0% survival D21-23; p<0.0001 vs tumor only and control T-cells).  Enhanced survival in mice receiving CAR T-cells correlated with a significant reduction in tumor burden by sequential (D7/14/21) bioluminescent imaging (p<0.01 at all timepoints), although residual tumor was identified in CAR treated mice over time. To assess for on-target off-tumor toxicity of murine LAIR1 CAR T-cells, pre-conditioned B6 recipients were given 5x106 control or CAR T-cells without tumor. Recipients (n=10/group, 2 experiments pooled) were monitored twice weekly for weight loss, weekly for clinical decline (skin ruffling, posture changes, reduced activity) and peripheral blood leukocyte (neutrophils, monocyte/macrophages, lymphocytes) counts and frequency. There were no differences in clinical or hematologic parameters between control and CAR T-cell groups over the course of 30D of monitoring post-infusion, suggesting minimal toxicity.

 

Ongoing experiments include the evaluation of human LAIR1 CAR T-cells efficacy in xenogeneic AML models and toxicity testing using human LAIR1 transgenic mice.

 

These data demonstrate successful initial preclinical testing of mouse and human LAIR1 CAR T-cells, including robust tumor elimination in in vitro studies, strong in vivo efficacy without toxicity in murine models and set the stage for further preclinical testing with human CAR T-cells as a potential prelude to early phase clinical trials with LAIR1 CAR T-cells for AML.
Valencia Williams: No relevant conflicts of interest to declare.